1Hajj ar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United Statcs, 1988-2000.JAMA 2003,290(2) : 199-206.
2Staessen JA, Gasowski J, Wang JG, et al . .. Risks of un- treated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355(9207), 865-72.
3Fedder DO, Koro CE, L'Italien GJ: New National Cho- lesterol Edusation Program Ⅲ guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-el- igible population. Circulation 2002,105(2) : 152-6.
4American diabetes Association.clinical practice remmen- dation. Diabetes Care 2002,25 ; S1-147.
5Pearson TA, Laurora I, Chu H, KMonek S.. The lipid treatment assessment project (L-TAP) : a multicenter survey to evaluate the percentages of dyslipidemic pa- tients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals. Arch Intern Med 2000,160(4), 459-67.
6EUROASP1RE. A European Society of Cardiology sur- vey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group, Europe- an Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997:1569-82.
7Clinical reality of coronary prevention guidelines., a com- parison of EROASPLRE Ⅰ and Ⅱ in nine countries: EROASPIRE I and II Group. European Action on Sec- ondary Prevention by Intervention to Reduce Events. Lancet 2001,357 : 995-1001.
8Bernard DB, Townsend RR, Sylvestri MF: Health and disease management: What is it and where is it going? What is the role of health and disease management in hypertension? Am JHypertens 1998,11 : 103-88.
9Yosefy C, Dicker D, Viskoper JR, Tulchinsky TH, Gins- berg GM, Leihovltz E, Gavish D: The Ashkelon Hyper- tension Detection and Control Program (AHDC Pro- gram) : a community approach to reducing cardiovascular mortality. Prev Med 2003,37(6) : 571-6.
10Yosefy C, Ginsberg GM, Dicker D, Viskoper JR, Tulchinsky TH, Leibovitz E, Gavish D, IBPC Investiga- tors: Risk factor profile and achievement of treatment goals among hypenensive patients from the Israeli Blood Pressure control (IBPC)program-initial cost untility analysis. Blood Press 2003,12(4) : 225-31.
